Japan’s Hisamitsu a pharmaceuticals and health goods manufacturer, has announced the purchase of US Miami-based Noven Pharmaceuticals for $430m.
The venture to make Noven a wholly owned subsidiary is part of Hisamitsu’s goal of growing its presence in the US.
Go deeper with GlobalData
Hisamitsu will pay $16.50 for each Noven share, representing a 38% premium on Noven’s 50-day moving average share price of $11.95.
The deal would make Noven a wholly owned subsidiary when completed in August, raising Hisamitsu’s stake in the firm up from its current 4.98% stake.
Noven, which specialises in hormone therapies for women as well as drug delivery patches, will name Jeffrey Eisenberg as president and chief executive and will remain a standalone business.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
